Adaptimmune Expects To Cut 62% of Staff After Cell Therapy Asset Sale

Adaptimmune Therapeutics has agreed to sell its four autologous T-cell therapy programs (TECELRA, lete-cel, afami-cel, uza-cel) to US WorldMeds for $55 million in cash, with up to $30 million in additional regulatory and commercial milestone payments245.

Post-acquisition, Adaptimmune will eliminate approximately 62% of its workforce, with significant severance costs projected at $7–8 million primarily hitting Q3 20252.

Senior executives—including the Chief Medical, Commercial, Scientific, and Financial Officers—will depart in August 2025 as part of the restructuring2.

US WorldMeds will assume selected liabilities, acquire manufacturing assets, and extend job offers to roughly half of Adaptimmune's current employees2.

The transaction is expected to close by August 4, 2025, pending customary conditions and no material adverse changes2.

Adaptimmune will retain its earlier-stage preclinical pipeline and plans to focus on advancing those programs following the asset divestiture4.

Sources:

2. https://www.stocktitan.net/sec-filings/ADAP/8-k-adaptimmune-therapeutics-plc-american-reports-material-event-664d0edb7d55.html

4. https://www.stocktitan.net/news/ADAP/adaptimmune-announces-entry-into-definitive-agreement-for-sale-of-049udj6jmdgg.html

5. https://sfbn.org/san-francisco-biotech-news/2025/07/28/adaptimmune-sells-4-cell-therapies-to-pharma-for-55m-plans-layoffs/